找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Integrating Multidisciplinary Treatment for Advanced Renal Cell Carcinoma; Rana R. McKay,Eric A. Singer Book 2023 The Editor(s) (if applic

[复制链接]
楼主: Encomium
发表于 2025-3-27 00:21:43 | 显示全部楼层
Subsequent Line Systemic Treatment Options for Advanced Renal Cell Carcinomaof care. Subsequently, the data for treatment options in second line and beyond has evolved. Recent phase 2/3 trials and retrospective analyses provide insights into treatment in the post-immunotherapy setting. It is crucial to compare the different types of treatments available to guide safe and ef
发表于 2025-3-27 02:22:24 | 显示全部楼层
发表于 2025-3-27 06:46:48 | 显示全部楼层
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcive radiation therapy (SAbR) at locations that were not previously feasible. While in the era of conventional protracted course radiation, renal cell cancer (RCC) was assessed to be radioresistant, and radiation therapy for RCC was even considered toxic, in the era of ablative hypofractionated radiat
发表于 2025-3-27 09:28:19 | 显示全部楼层
Systemic Therapies for Advanced Non-Clear Cell Renal Cell Carcinoma RCC comprises a heterogeneous group of tumors—from the initial description of two subtypes in 1952 (clear cell and granular cell), the classification of kidney cancer has evolved to recognize a large variety of histological subtypes according to the World Health Organization (WHO), and over 50 gene
发表于 2025-3-27 14:12:20 | 显示全部楼层
发表于 2025-3-27 19:55:57 | 显示全部楼层
发表于 2025-3-27 22:29:16 | 显示全部楼层
Predictive Biomarkers in Advanced Renal Cell Carcinomas with advanced renal cell carcinoma. Although many of these biomarkers are not fully validated, initial investigations are promising. This chapter will explore our current knowledge of novel predictive biomarkers and discuss how they may be integrated into routine clinical use.
发表于 2025-3-28 06:02:32 | 显示全部楼层
First-Line Systemic Treatment Options for Advanced Renal Cell Carcinomaapproved ICI combinations: ipilimumab/nivolumab, axitinib/pembrolizumab, axitinib/avelumab, cabozantinib/nivolumab, and lenvatinib/pembrolizumab. Challenges and approaches to therapeutic choices are also explored.
发表于 2025-3-28 08:52:37 | 显示全部楼层
Role of Primary and Metastasis-Directed Stereotactic Radiation Therapy for Advanced Renal Cell Carcition of SAbR with other local and systemic therapies is key in the optimal management of RCC patients. This chapter will discuss the rationale and available evidence for the integration and sequencing of SAbR with local and systemic therapies for RCC.
发表于 2025-3-28 13:15:15 | 显示全部楼层
Radical Nephrectomy for Renal Cell Carcinomanefit. Management of RCC utilizing RN requires careful consideration of tumor size, location, local anatomy, and potential complication to select the proper technique and approach. This chapter reviews and describes relevant techniques, approaches, indications, outcomes, and considerations.
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-8 06:38
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表